News | Wearables | August 15, 2019

Bardy Diagnostics Selected for HealthTech Arkansas Accelerator Program

Carnation Ambulatory Monitor is one of six healthcare tech startups chosen from hundreds of submissions to partner with hospitals throughout Arkansas

Bardy Diagnostics Selected for HealthTech Arkansas Accelerator Program

August 15, 2019 — Bardy Diagnostics Inc. announced that HealthTech Arkansas, a healthcare accelerator and investment fund that connects early-stage healthcare companies with disruptive technologies to Arkansas healthcare providers, has selected BardyDx to participate in the organization's 2019 accelerator program. BardyDx was chosen for its advancements in cardiac monitoring by delivering diagnostic accuracy with the Carnation Ambulatory Monitor (CAM), a P-wave centric ambulatory cardiac patch monitor and arrhythmia detection device.

HealthTech Arkansas is a new and expanded iteration of two previous accelerator programs in the state, Health InnovatAR and HubX-LifeSciences. This year, with more provider partners and increased investment for participating companies, HealthTech Arkansas is focused on bringing the most innovative healthcare technologies to Arkansas. The 2019 cohort selection was announced at the Arkansas Heart Hospital with a welcome from CEO Bruce Murphy, M.D., Ph.D., followed by a message from Arkansas Gov. Asa Hutchinson and presentations from each of the six chosen companies. Both Murphy and Hutchinson focused on the importance of working together to bring innovative technologies to Arkansas.

This year's six companies were selected from hundreds of applicants across 18 different countries. The cohort will participate in a program that provides them the opportunity to partner with and build solutions specifically identified by Arkansas Heart Hospital, Arkansas Children's, Arkansas Urology, Baptist Health, CHI St. Vincent, Conway Regional, Mercy, the University of Arkansas for Medical Sciences (UAMS) and Washington Regional Medical Center as areas of opportunity within their organizations. Each of the cohort companies will receive seed investment as well as complete and total access to clinicians and administrators at each partnering site.

"We're delighted to have the participation of BardyDx as one of six companies in our cohort this year," said Jeff Stinson, Director of HealthTech Arkansas. "Collectively, they're among the most accomplished early-stage healthcare companies in the country. BardyDx was specifically chosen because the leadership teams in our partner hospitals believe the company can significantly increase the quality of care through its innovative devices. We can't wait to begin our work with BardyDx."

For more information: www.bardydx.com

Related Content

The Mesuron Inc. Avalon-H90 uses magnetometers to detect myocarditis in patients without any physical contact. It uses ventricular repolarization dynamics analysis software to look for abnormalities. The vendor said it is more specific than using ECG. It detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential of normal heart tissues and abnormal ones with hypoxia.

The Mesuron Inc. Avalon-H90 uses magnetometers to detect myocarditis in patients without any physical contact. It uses ventricular repolarization dynamics analysis software to look for abnormalities. The vendor said it is more specific than using ECG. It detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential of normal heart tissues and abnormal ones with hypoxia. 

News | Cardiac Diagnostics | October 06, 2020
October 6, 2020 — A new technology being developed by U.S.-based Mesuron Inc.
With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a costly tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. Amyloidosis Patient Registry  #Amyloidosis

With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. This is Figure 2, showing how SPECT imaging allows the reader to distinguish between blood pool activity (ventricular cavity, etc) and myocardial activity and identify regional myocardial differences in radiotracer uptake.

News | Cardiac Diagnostics | March 05, 2020
March 5, 2020 — More than 300 patients have joined the Amyloidosis Patient Registry and it is now available to the en
heart disease image
News | Cardiac Diagnostics | December 18, 2019
December 18, 2019 — In their latest report, “...
FDA Warns Troponin Tests Impacted by Biotin Dietary Supplement
Feature | Cardiac Diagnostics | November 05, 2019 | Dave Fornell, Editor
November 5, 2019 — The U.S.
Videos | Cardiac Diagnostics | October 29, 2019
Doctor Clyde Yancy was a keynote speaker and said doctors need to check their assumptions about patients at the door...
79-year-old Tony Marovic had a right carotid endarterectomy shortly after discovering a 95 percent blockage of his carotid artery at a health and wellness screening event

79-year-old Tony Marovic had a right carotid endarterectomy shortly after discovering a 95 percent blockage of his carotid artery at a health and wellness screening event. Image courtesy of University Hospitals.

News | Cardiac Diagnostics | October 16, 2019
Health and wellness screenings are more than just nice events for the community – they can save lives. A Mentor, Ohio,...
Pesticide Exposure May Increase Heart Disease and Stroke Risk

Image courtesy of zefe wu from Pixabay

News | Cardiac Diagnostics | October 15, 2019
On-the-job exposure to high levels of pesticides raised the risk of heart disease and stroke in a generally healthy...
World Heart Federation Launches Global Roadmap on Cardiovascular Disease Prevention Among Diabetics
News | Cardiac Diagnostics | September 04, 2019
At the European Society of Cardiology (ESC) Congress 2019 together with the World Congress of Cardiology, the World...